Utility of Immunohistochemical Markers in the Differential Diagnosis of Uterine Papillary Serous Carcinomas and Uterine Endometrioid Carcinomas

Kyu-Rae Kim · Dong Eun Song*
Department of Pathology, University of Ulsan College of Medicine, Asan Medical Center, Department of Pathology,* Ewha Womans University School of Medicine

Purpose: Because uterine papillary serous carcinomas have a worse clinical outcome compared with uterine endometrioid carcinomas, there is a need for a more specific diagnosis. The purpose of this study was to find immunohistochemical markers that could be helpful in differentiating between these two types of tumors.

Method: We studied paraffin-embedded tissue from 19 cases of low-grade endometrioid carcinoma, 19 cases of high-grade endometrioid carcinoma, and 13 cases of papillary serous carcinoma for MLH1, MSH2, p53, PTEN, c-erb B2, estrogen receptor (ER), progesterone receptor (PR), E-cadherin, and β-catenin.

Results: Papillary serous carcinoma showed higher p53 expression compared to high-grade endometrioid carcinoma (p=0.003). Low-grade endometrioid carcinoma had more p53 expression compared to papillary serous carcinoma (p<0.001) and showed increased expression of ER (p<0.001) and PR (p=0.038).

Conclusion: Immunohistochemical changes for p53 were useful for distinguishing between these two types of tumors. However, a combination of p53(+) and ER(-) and PR(-) will be more helpful for distinguishing between low-grade endometrioid carcinoma and papillary serous carcinoma.

Key Words: Papillary serous carcinoma · Endometrioid carcinoma · Immunohistochemical markers.

Address for correspondence: Dong Eun Song, MD
Department of Pathology, Ewha Womans University School of Medicine, Mokdong Hospital, 911-1 Mok-dong, Yangcheon-gu, Seoul 158-710, Korea
Tel: (02) 2650–5832 · FAX: (02) 2650–4635 · E-mail: hipuha@ewha.ac.kr
Introduction

Uterine papillary serous carcinomas (UPSCs) demonstrate distinct histological features such as a high degree of cytological atypia and a papillary growth pattern\(^1\). UPSCs follow the similar mode of spread to that of ovarian surface epithelial carcinomas\(^2\). The histological distinction between UPSCs and endometrioid adenocarcinomas (EMCs) is of paramount importance because UPSCs follow a more aggressive clinical course and higher relapse rate than EMCs\(^3\). Tumor recurrence was reported to be more frequent in UPSCs than EMCs with the 1988 International Federation of Gynecology and Obstetrics (FIGO) grade 3\(^4\). Even a small percentage of UPSCs (even 10%) in a mixed form of carcinomas is correlated with a poor prognosis\(^5\). Thus, definitive preoperative or intraoperative diagnosis for UPSCs in patients with low FIGO stage ensures optimal surgical treatment and adjuvant radio-chemotherapy.

UPSCs and EMCs are well known to have different genetic pathways suggesting the dualistic model of endometrial tumorigenesis\(^6\)\(^8\). In UPSCs, p53 mutation, inactivation of E-cadherin and amplification of c-erb B2 are well known\(^9\). p53 mutation was reported even in the endometrial intraepithelial carcinoma, a putative precursor of UPSCs\(^9\). In EMCs, inactivation of PTEN, microsatellite instability (MSI) and mutations of K-ras and β-catenin are well known\(^10\). Although the expression pattern of immunohistochemical markers associated with molecular pathways is considered to depend upon the histological subtypes of endometrial carcinomas, useful biomarkers to differentiate UPSCs from the EMCs, particularly FIGO grade 3 EMCs, are not well established.

We aimed to determine whether there are useful immunohistochemical markers applicable to the differential diagnosis between UPSCs and EMCs using paraffin sections.

Materials and Methods

1. Case selection and tissue microarray

Among two hundreds ten cases of EMCs and 15 cases of UPSCs from the surgical pathology files at Asan Medical Center (Seoul, South Korea) between 2001 and 2006, the selected cases included 19 low-grade EMCs (FIGO grade 1 or 2), 19 high-grade EMCs (FIGO grade 3), and 13 UPSCs.

All tissues had been routinely fixed in 4% buffered formaldehyde and processed into paraffin blocks. Two pathologists reviewed the slides to select appropriate blocks for tissue microarray.

We created one tissue microarray slide for each group, each containing three 1-mm-diameter cores per case to decrease the risk of aberrant results due to tumor heterogeneity. Briefly, representative areas of each tumor were selected and marked on the H&E slide. After extracting cores of wax (0.8mm diameter) from three prepared empty paraffin blocks, each core was replaced with the core (1mm diameter) obtained from its corresponding tissue block. Once the punches were complete, all blocks were sealed in a 60°C oven for 10min.

2. Immunohistochemistry

A panel of immunohistochemical stainings included MLH1 (1: 50 : Pharmingen, San Diego, Calif), MSH2 (1: 250 : Pharmingen, San Diego, Calif), p53 (1: 1,600 : DAKO, Carpinteria, U.S.A.), PTEN (1: 100, Novocastra, England), c-erb B2 (1: 500 : Dako, Carpinteria, U.S.A.), estrogen receptor (ER, 1: 50 : Dinona, Seoul, Korea), progesterone receptor (PR, 1: 100 : Dinona, Seoul, Korea), E-cadherin (1: 100 : ZYMED, San Francisco, U.S.A.), and β-catenin (1: 500 : ZYMED, San Francisco, U.S.A.). All immunostainings were performed in the Benchmark automatic immunostaining device (Ventana Medical System, Tucson, Ariz) using formalin-fixed, paraffin-embedded tissue sections. Five-micrometer-thick sections were obtained by microtome, transferred onto adhesive slides, and dried at 62°C for 30minutes. After dewaxing and rehydrating procedures, antigen retrieval was carried out in all cases. After incubation with primary antibodies, the sections were incubated with biotinylated antimouse immunoglobulins, followed by peroxidase-labeled streptavidin in the LSAB kit (DAKO) and 3,3’-diaminobenzidine chromogen as substrate. Negative controls were obtained by omitting the primary antibodies for all slides. Slides were counterstained with Harris hematoxylin.
3. Evaluation of immunostaining

Two pathologists analyzed slides to examine any differences in intensity, percent positivity, and staining patterns among 3 groups. The results were considered significant for MLH1 or MSH2 if 100% of tumor cells lost nuclear staining. p53 immunostaining was interpreted as significant when at least two thirds of tumor cells showed nuclear staining. PTEN immunostaining was interpreted as significant when at least 90% of tumor cells lost nuclear staining. ER or PR immunostaining was interpreted as significant when at least 10% of tumor cells demonstrated nuclear staining of moderate to strong intensity. β-catenin immunostaining was considered significant when tumor cells showed any nuclear or cytoplasmic staining. E-cadherin immunostaining was interpreted as significant when more than 25% of tumor cells lost membranous staining. C-erb-B2 immunostaining was considered significant when at least 10% of tumor cells showed complete membranous staining of moderate to strong intensity.

4. Statistical analysis

Statistical analysis between groups was performed using SPSS software (version 10; SPSS Inc., Chicago, Ill.). The χ² test and Fisher’s exact probability test were used to see any differences in the significant immunohistochemical results. P-values of less than 0.05 were considered to be significant.

Results

The results of immunohistochemical findings among 3 groups are summarized in Table 1. Cases of EMCs, low grade (Fig. 1) demonstrated significant immunohistochemical results for MLH1 (10.5%), MSH2 (15.8%), p53 (5.3%), PTEN (42.3%), ER (89.5%), PR (89.5%), β-catenin (31.6%), E-cadherin (10.5%), and c-erb B2

| Table 1. Significant results of immunohistochemical stainings in EMCs and UPSCs |
|-------------------------------|-----------------|-----------------|-----------------|
| No. (%) | EMCs, low grade | EMCs, high grade | UPSCs |
| MLH1 | 2/19 (10.5%) | 6/19 (31.6%) | 2/13 (15.4%) |
| MSH2 | 3/19 (15.8%) | 7/19 (36.8%) | 2/13 (15.4%) |
| p53 | 1/19 (5.3%) | 4/19 (21.1%) | 10/13 (76.9%) |
| PTEN | 8/19 (42.3%) | 2/19 (10.5%) | 2/13 (15.4%) |
| ER | 17/19 (89.5%) | 3/19 (15.8%) | 1/13 (7.7%) |
| PR | 17/19 (89.5%) | 7/19 (36.8%) | 7/13 (53.8%) |
| β-catenin | 6/19 (31.6%) | 4/19 (21.1%) | 2/13 (15.4%) |
| E-cadherin | 2/19 (10.5%) | 7/19 (36.8%) | 5/13 (38.5%) |
| c-erb-B2 | 2/19 (10.5%) | 4/19 (21.1%) | 2/13 (15.4%) |

EMCs: endometrioid carcinomas, UPSCs: uterine papillary serous carcinomas

Fig. 1. Low-grade endometrial carcinomas (EMCs, LG) show an immunophenotype of p53 (−, left), ER (+, middle) and PR (+, right) in nuclei of tumor cells (×200).
(10.5%), respectively. Cases of EMCs, high grade demonstrated significant immunohistochemical results for MLH1 (31.6%), MSH2 (36.8%), p53 (21.1%), PTEN (10.5%), ER (15.8%), PR (36.8%), β-catenin (21.1%), E-cadherin (36.8%), and c-erb B2 (21.1%), respectively. Cases of UPSCs (Fig. 2) demonstrated significant immunohistochemical results for MLH1 (15.4%), MSH2 (15.4%), p53 (76.9%), PTEN (15.4%), ER (7.7%), PR (53.8%), β-catenin (15.4%), E-cadherin (38.5%), and c-erb B2 (15.4%), respectively.

Cases of the UPSCs showed significantly more frequent immunopositivity for p53 immunohistochemical staining than those of the EMCs, high grade (ER: p<0.0001 and PR: p=0.002) by the χ² test. However, immunopositivity for both ER (p=0.629) and PR (p=0.473) immunohistochemical stainings demonstrated no significant difference in the differential diagnosis of the UPSCs from the EMCs, high grade by the χ² test. The remaining immunohistochemical markers showed no significant difference among 3 groups.

The utility of immunohistochemical stainings in the differential diagnosis of the UPSCs from the EMCs is summarized in Table 2. The combined use of both immunonegativity for ER and immunopositivity for p53 increased the specificity in the differential diagnosis of the UPSCs from the EMCs regardless of FIGO grades (Table 2).

**Discussion**

The tumorigenesis of sporadic endometrial cancer has
been explained by a dualistic model from both biological and clinical parameters. Type-I EMCs, about 70–80% of cases of endometrioid carcinomas, follow an estrogen related pathway, develop in pre- and peri-menopausal women, frequently preceded by endometrial hyperplasia, express ER and PR receptors and are characterized by a favorable prognosis. Type-II UPSCs, about 10–20% of cases of endometrioid carcinomas, follow an estrogen unrelated pathway, develop in post-menopausal women, frequently preceded by atrophic endometrium or endometrial intraepithelial carcinoma, demonstrate p53 mutation and are characterized by a aggressive clinical course.

Molecular genetics have recently provided us with more data supporting the dualistic model of type-I and type-II endometrial carcinomas.

In EMCs, 25–30% of MSI was previously reported in the literature, and lower frequency (10–15%) of MSI was observed in our cases of EMCs, low-grade. 5–37% of p53 mutation or overexpression was previously reported in the literature, similar to our study (5–21%). Cases of EMCs, high-grade demonstrated significantly increased p53 overexpression (21%) than EMCs, low-grade (5%) in our study although as much as 66% of p53 overexpression was reported in cases of EMCs, FIGO grade 3. Similarly, p53 overexpression was reported to be associated with high grade, advanced stage tumors and worse outcome. Loss of PTEN expression, the most frequently altered gene in EMCs, was observed in 42% of EMCs, low-grade, 5–35% of the previous report, similar to our study (5–21%). Cases of EMCs, high-grade demonstrated significantly increased p53 overexpression (21%) than EMCs, low-grade (5%) in our study although as much as 66% of p53 overexpression was reported in cases of EMCs, FIGO grade 3. Similarly, p53 overexpression was reported to be associated with high grade, advanced stage tumors and worse outcome.

Loss of PTEN expression, the most frequently altered gene in EMCs, was observed in 42% of EMCs, low-grade, 5–35% of the previous report, similar to our study (5–21%). Cases of EMCs, high-grade demonstrated significantly increased p53 overexpression (21%) than EMCs, low-grade (5%) in our study although as much as 66% of p53 overexpression was reported in cases of EMCs, FIGO grade 3. Similarly, p53 overexpression was reported to be associated with high grade, advanced stage tumors and worse outcome.

Loss of PTEN expression, the most frequently altered gene in EMCs, was observed in 42% of EMCs, low-grade, 5–35% of the previous report, similar to our study (5–21%). Cases of EMCs, high-grade demonstrated significantly increased p53 overexpression (21%) than EMCs, low-grade (5%) in our study although as much as 66% of p53 overexpression was reported in cases of EMCs, FIGO grade 3. Similarly, p53 overexpression was reported to be associated with high grade, advanced stage tumors and worse outcome.

Loss of PTEN expression, the most frequently altered gene in EMCs, was observed in 42% of EMCs, low-grade, 5–35% of the previous report, similar to our study (5–21%). Cases of EMCs, high-grade demonstrated significantly increased p53 overexpression (21%) than EMCs, low-grade (5%) in our study although as much as 66% of p53 overexpression was reported in cases of EMCs, FIGO grade 3. Similarly, p53 overexpression was reported to be associated with high grade, advanced stage tumors and worse outcome. Loss of PTEN expression, the most frequently altered gene in EMCs, high-grade of our study. Similarly, E-cadherin expression in EMCs was reported to be negatively correlated with tumor grade and may be an independent prognostic factor for disease progression. C-erb B2 expression was higher in EMCs, high-grade than EMCs, low-grade in our study similar to the previous report.

In UPSCs, MSI was uncommon and showed no significant difference between UPSCs and EMCs in our study unlikely to the previous report. 80% to more than 90% of p53 mutation or overexpression was previously reported in the literature for UPSCs, which is higher than that of our study. It is remarkable p53 immunohistochemical staining is the most sensitive single marker in the differential diagnosis of the UPSCs from the EMCs regardless of FIGO grades (Table 2). ER and PR expression was significantly decreased in UPSCs similar to the previous reports. Although no expression of β-catenin was reported in the previous report for UPSCs, our study demonstrated 15% of β-catenin expression. As much as 62% of loss of E-cadherin expression was reported in the previous report for UPSCs, which is much higher than that (38%) of our study. Although significant difference in the E-cadherin expression was reported between endometrioid cell type and papillary serous or clear cell types, our study showed no difference between two cell types. C-erb B2 expression in UPSCs (15%) was lower than those of previous reports. Although significant difference in the expression of c-erb B2 was reported between UPSCs and EMCs, any FIGO grade in the previous report, our study revealed no difference among three groups. Among variable markers, only p53, ER and PR showed significant difference between UPSCs and EMCs, low-grade in our study.

This study is unique in that it is the most extensive comparative immunohistochemical study of uterine carcinomas comparing the similar previous studies. Similar to our study, only p53 was useful to differentiate UPSCs from EMCs, FIGO grade 3 among p53, PTEN, and c-erb B2 by N. Macwhinnie and H. Monaghan. F. Darvishian et al. concluded only p53, PR, and PTEN best distinguished between EMCs and UPSCs mimicking EMCs with well-differentiated tubuloglandular morphology but high nuclear grade among p53, ER, PR,
PTEN, cyclin D1, and β-catenin. For ER, PR, and p53, the same trend was previously reported among three groups to our study. The present study also adds evidence that the combined immunohistochemical analysis of endometrial carcinomas including p53, ER, or PR can more effectively differentiate between different grades and histological types (Table 2) than a use of single immunohistochemical marker. Although no mixed endometrial carcinoma is included in this study, these combined immunohistochemical analysis may be helpful in the distinction of mixed UPSCs and high-grade EMCs from pure high-grade EMCs as well as the distinction of EMCs of villoglandular features from UPSCs.

**Conclusion**

Immunohistochemical expression of p53 is a useful tool for differentiating UPSCs from EMC regardless of FIGO grade. Combined immunohistochemical results of p53(+) ER(−), and PR(−) would best characterize the UPSCs, and the low-grade EMCs would be best characterized by the opposite results.

**References**

1) Hendrickson M, Ross J, Eifel P, Martinez A, Kempson R: Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma. Am J Surg Pathol 1982; 6: 93-108
2) Burrell MO, Franklin EW, 3rd, Powell JL: Endometrial cancer: evaluation of spread and follow-up one hundred eighty-nine patients with Stage I or Stage II disease. Am J Obstet Gynecol 1982; 144: 181-185
3) Prat J: Prognostic parameters of endometrial carcinoma. Hum Pathol 2004; 35: 649-662
4) Cirisano FD, Jr., Robboy SJ, Dodge RK, Bentley RC, Krigman HR, Synan IS, et al: The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma. Gynecol Oncol 2000; 77: 55-65
5) Boruta DM, 2nd, Gehrig PA, Groben PA, Bac-Jump V, Boggess JF, Fowler WC Jr, et al: Uterine serous and grade 3 endometrioid carcinomas: is there a survival difference? Cancer 2004; 101: 2214-2221
6) Lax SF: Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification. Virchows Arch 2004; 444: 213-223
7) Cao QJ, Belbin T, Socci N, Balan R, Prystowsky MB, Childs G, et al: Distinctive gene expression profiles by cDNA microarrays in endometrioid and serous carcinomas of the endometrium. Int J Gynecol Pathol 2004; 23: 321-329
8) Abal M, Planaguma J, Gil-Moreno A, Monge M, Gonzalez M, Baro T, et al: Molecular pathology of endometrial carcinoma: transcriptional signature in endometrioid tumors. Histol Histopathol 2006; 21: 197-204
9) Tashiro H, Isaacs C, Levine R, Kurman RJ, Cho KR, Hedrick L: p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis. Am J Pathol 1997; 150: 177-185
10) Lax SF, Kurman RJ: A dualistic model for endometrial carcinogenesis based on immunohistochemical and molecular genetic analyses. Virchows Arch 1997; 81: 228-232
11) Lax SF, Kendall B, Tashiro H, Slebos RJ, Hedrick L: The frequency of p53, K-ras, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways. Cancer 2000; 88: 814-824
12) Kounelis S, Kapranos N, Kouri E, Coppola D, Papadaki H, Jones MW: Immunohistochemical profile of endometrial adenocarcinoma: a study of 61 cases and review of the literature. Mod Pathol 2000; 13: 379-388
13) Macwhinnie N, Monaghan H: The use of P53, PTEN, and C-erbB-2 to differentiate uterine serous papillary carcinoma from endometrioid endometrial carcinoma. Int J Gynecol Cancer 2004; 14: 938-946
14) Alkushi A, Lim P, Coldman A, Huntsman D, Miller D, Gilks CB: Interpretation of p53 immunoreactivity in endometrial carcinoma: establishing a clinically relevant cut-off level. Int J Gynecol Pathol 2004; 23: 129-137
15) Halperin R, Zehavi S, Habler L, Hadad E, Bukovsky I, Schneider D: Comparative immunohistochemical study of endometrioid and serous papillary carcinoma of endometrium. Eur J Gynaecol Oncol 2001; 22: 122-126
16) Reid-Nicholson M, Iyengar P, Hummer AJ, Linkov I, Asher M, Soslow RA: Immunophenotypic diversity of endometrial adenocarcinomas: implications for differential diagnosis. Mod Pathol 2006; 19: 1091-1100
17) Shedden KA, Kshirsagar MP, Schwartz DR, Wu R, Yu H, Misek DE, et al: Histologic type, organ of origin, and Wnt pathway status: effect on gene expression in ovarian and uterine carcinomas. Clin Cancer Res 2005; 11: 2123-2131
18) Schlosshauer PW, Ellenson LH, Soslow RA: Beta-catenin and E-cadherin expression patterns in high-grade endometrial carcinoma are associated with histological subtype. Mod Pathol 2002; 15: 1032-1037
19) Holcomb K, Delatorre R, Pedemonte B, McLeod C, Anderson L, Chambers J: E-cadherin expression in endometrioid, papillary serous, and clear cell carcinoma of the endometrium. Obstet Gynecol 2002; 100: 1290-1295
20) Mell LK, Meyer JJ, Tretiakova M, Khramtsov A, Gong C, Yamada SD, et al: Prognostic significance of E-cadherin protein expression in pathological stage I-III endometrial cancer. Clin Cancer Res 2004; 10: 5546-5553
21) Morrison C, Zanagnolo V, Ramirez N, Cohn DE, Kelbick N, Copeland L, et al: HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients. J Clin Oncol 2006; 24: 2376-2385
22) Tashiro H, Lax SF, Gaudin PB, Isacson C, Cho KR, Hedrick L: Microsatellite instability is uncommon in uterine serous carcinoma. Am J Pathol 1997; 150: 75-79
23) Egan JA, Ionescu MC, Eapen E, Jones JG, Marshall DS: Differential expression of WT1 and p53 in serous and endometrioid carcinomas of the endometrium. Int J Gynecol Pathol 2004; 23: 119-122
24) Darvishian F, Hummer AJ, Thaler HT, Bhargava R, Linkov I, Asher M, et al: Serous endometrial cancers that mimic endometrioid adenocarcinomas: a clinicopathologic and immunohistochemical study of a group of problematic cases. Am J Surg Pathol 2004; 28: 1568-1578